BRAF V600 mutation (DBCOND0025013)

Identifiers

Synonyms

BRAFV600 Mutation / BRAF V600

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01843738	Radiation Use During Vemurafenib Treatment	Vemurafenib	treatment	1	withdrawn
NCT03663647	Advanced Melanoma in Russian Experience	No drug interventions	Not Available	Not Available	completed
NCT04911998	A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients	No drug interventions	Not Available	Not Available	recruiting
NCT05786924	A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers	No drug interventions	treatment	1	recruiting
NCT05800340	Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC	Carboplatin Paclitaxel Pemetrexed Toripalimab	treatment	2	recruiting
NCT05501912	A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors	No drug interventions	treatment	1	recruiting
NCT05510895	Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer	Binimetinib Cetuximab Encorafenib	treatment	2	recruiting
NCT03430947	Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases	Cobimetinib Vemurafenib	treatment	2	terminated
NCT05546905	A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)	No drug interventions	Not Available	Not Available	recruiting
NCT04741997	Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma	Binimetinib Encorafenib Nivolumab	treatment	0	recruiting
NCT04190628	Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors	Cobimetinib	treatment	1	terminated
NCT04074096	Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis	Binimetinib Encorafenib Pembrolizumab	treatment	2	active_not_recruiting
NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	Trametinib XP-102	treatment	1 / 2	not_yet_recruiting
NCT06054191	Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations	Capmatinib Dabrafenib Trametinib	treatment	2	not_yet_recruiting
NCT05103891	Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations	Binimetinib	other	1	unknown_status
NCT05810740	Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations	Binimetinib	other	1	completed
NCT03514901	To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	Nivolumab Pembrolizumab	treatment	2	unknown_status
NCT04759846	Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma	Binimetinib Encorafenib	treatment	1	withdrawn
NCT04775095	BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation	No drug interventions	Not Available	Not Available	completed